What changed in this filing

/stocks — the workspaceLOADING

Item 1. Legal Proceedings

2025-02-11 compared with 2024-11-13 · 33 added, 24 removed, 7 unchanged (89% of the section changed)

3 unchanged sentences

material legal proceeding or contemplated or threatened litigation, other than as described below.

There are no judgments against us or

our officers or directors.

None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance

in corporate office.

On January 19, 2024, a purported shareholder class action complaint,

captioned Eric Olmstead v.

There are no judgments against the

Company or our officers or directors.

None of our officers or directors has been convicted of a felony or misdemeanor relating to securities

or performance in corporate office.

On January 19, 2024, a purported shareholder class

action complaint, captioned Eric Olmstead v.

3:24-cv-00035, was filed in the U.S.

District Court for the District of Nevada, naming

the Company and certain of its officers as defendants.

On February 22, 2024, a second, related putative securities class action was filed

in the same court asserting similar claims against the same defendants, captioned Way v.

District Court for the District

of Nevada, naming the Company and certain of its officers as defendants.

On February 22, 2024, a second, related putative securities class

action was filed in the same court asserting similar claims against the same defendants, captioned Way v.

2:24-cv-00361.

15, 2024, the court consolidated these two actions under the caption In re BioVie Inc.

On April 15, 2024, the court consolidated these two actions under the caption In re BioVie Inc.

Securities Litigation, No.

3:24-cv-00035, appointed

the lead plaintiff, and approved selection of the lead counsel.

On June 21, 2024, the lead plaintiff filed an amended complaint, alleging

that the defendants made material misrepresentations and/or omissions of material fact relating to the Company’s business, operations,

compliance, and prospects, including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate

probable AD, in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder.

The class action is

on behalf of purchasers of the Company’s securities during the period from December 7, 2022 through November 28, 2023 and seeks

unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees.

defendants filed a motion to dismiss the amended complaint on August 21, 2024, and plaintiffs filed their opposition on October 21, 2024.

The defendants’ reply brief is due December 5, 2024.

The defendants believe that the claims are without merit and intend to defend

vigorously against them, but there can be no assurances as to the outcome.

3:24-cv-00035,

appointed the lead plaintiff, and approved selection of the lead counsel.

On June 21, 2024, the lead plaintiff filed an amended complaint,

alleging that the defendants made material misrepresentations and/or omissions of material fact relating to the Company’s business,

operations, compliance, and prospects, including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild

to moderate probable AD, in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder.

action is on behalf of purchasers of the Company’s securities during the period from December 7, 2022 through November 28, 2023

and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s

The defendants filed a motion to dismiss the amended complaint on August 21, 2024, and plaintiffs filed their opposition on October

The defendants’ reply brief was filed December 5, 2024.

The defendants believe that the claims are without merit and intend

to defend vigorously against them, but there can be no assurances as to the outcome.

On December 30, 2024, a shareholder derivative lawsuit was filed in the

United States District Court for the District of Nevada by putative stockholder Andrew Hulm, allegedly on behalf of the Company, that

piggy-backs on the securities class action also pending in that court.

The derivative complaint names certain current and former officers

and directors as defendants, and generally alleges that they breached their fiduciary duties by causing or failing to prevent the securities

violations alleged in the securities class action.

The derivative complaint also alleges claims for unjust enrichment, waste of corporate

assets, gross mismanagement, and abuse of control as against all defendants.

The defendants believe that the claims are without merit

and intend to defend vigorously against them, but there can be no assurances as to the outcome.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Legal Proceedings